Video

Dr. Garassino on Safety Protocols for Patients With Cancer in Italy During COVID-19

Marina Chiara Garassino, MD, discusses key safety protocols that were initiated for patients with cancer in Italy during the COVID-19 pandemic.

Marina Chiara Garassino, MD, professor of medicine, Department of Medicine, Section of Hematology/Oncology, Knapp Center for Biomedical Discovery, The University of Chicago, discusses key safety protocols that were initiated for patients with cancer in Italy during the COVID-19 pandemic.

At the start of the COVID-19 pandemic, hospitals and cancer centers in Italy tried to delay all non-essential treatments for patients with cancer, including CT scans and MRIs, says Garassino.

After the first wave of COVID-19 infections, improved organization within cancer centers allowed normal care to be reinstated, Garassino explains. However, the inability for patients to bring someone with them to the clinic was a significant limitation of the safety protocols put in place, Garassino says. Additionally, patients were required to have a COVID-19 test before they were treated, change their masks frequently, and wash their hands frequently, Garassino says.

With those safety measures in place, as well as having a separate wing or area of the hospital reserved for patients with COVID-19, patients with cancer were generally protected against getting COVID-19 in the hospital, concludes Garassino.

Related Videos
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD